Aim: There is currently a need to identify prognostic biomarkers to assist in a risk adopted approach in treatment of malignant pleural mesothelioma (MPM). Expression of programmed death ligand 1 (PD-L1) has been studied as a prognostic biomarker in a number of tumors given its central role in antitumoral immune response evasion. Four previously published analyses found PD-L1 positivity to be an adverse survival prognostic factor in MPM. This study aims to further investigate the relationship between PD-L1 expression in mesothelioma tissues and survival outcome.
INTRODUCTION
Malignant pleural mesothelioma (MPM) is a rare but highly aggressive malignancy of the mesothelial surface of the pleura predominantly caused by exposure to asbestos. The Australian Mesothelioma Registry reports an incidence of 641 of newly diagnosed mesothelioma cases annually. 1 There is significant heterogeneity in survival of patients with MPM. Median survival of untreated MPM has been reported to range between 8 and 12 months, although small percentage of long-term survivors are recognized. 2 A multidisciplinary management approach is usually used for patient with MPM. There is currently no proven survival advantage with surgical resection, and combination chemotherapy with a platinum-based doublet such as cisplatin plus pemetrexed is the most widely used regimen. This is based on a phase III trial that demonstrated modest prolongation of overall survival compared to cisplatin alone. 3 There is an increasing need to identify prognostic markers which will help to predict behavior in MPM and individualize therapy based on risk adopted approach. Older age, male gender and sarcomatoid histological subtypes have been shown to correlate with poor survival. 4 Epithelioid subtype has a median survival of 14.8 months, not classified subtype, 13.9 months, biphasic subtype 9.1 months, and 4 Clinical variable such as weight loss, anemia, hypoalbuminemia and platelet count are also other poor prognostic factors. 5 Expression of programmed death ligand 1 (PD-L1) has been studied in several tumors as a prognostic biomarker. PD-L1 is an inhibitory ligand, which binds to the program-cell death-1 transmembrane protein expressed on T cells, B cells and NK cells. The interaction between PD-1 and PD-L1 result in direct inhibition of apoptosis of tumor cell, and promoting peripheral T effector cell exhaustion. Positive PD-L1 expression was found to be a negative predictor for cancer-specific survival in renal cell carcinoma, 6 stage II/III gastric cancer, 7 and as an independent prognostic factor in localized GIST. 8 Four previously published analyses found PD-L1 positivity to be an adverse prognostic factor for survival in MPM. [9] [10] [11] [12] In addition, checkpoint inhibitors, PD-1 and PD-L1 inhibitors have been increasingly used in treatments of solid tumors. A preliminary report, and a phase II trial has shown that anti-PD-L1 antibody may be used as a new treatment option for MPM. 13, 14 This study aims to investigate the PD-L1 expression profile of patient with MPM in our institution's database and correlative relationship between PD-L1 expression in mesothelioma tissues and survival time.
METHODS
In this retrospective study, patients who had a histological diagnosis 
Immunohistochemistry analysis
Formalin fixed paraffin-embedded pleural biopsies were reviewed for routine histopathology and immunohistochemistry (IHC). IHC analysis was carried out on sections that were deparaffinized in an oven for 30 min at 60 • C followed by three serial xylene incubations. The antigen was heat retrieved using CCI pH 8-8.5 for 64 min. IHC using VENTANA rabbit monoclonal primary PD-L1 antibody (clone SP263) was carried out using 4-mm-thick FFPE tissue sections on a Benchmark 
Statistical analysis
Overall survival was calculated from time of diagnosis of MPM until death due to any cause. We used the Statistical Software R (version 3.3.2) to perform the survival analysis, and specifically the "survival" package. 15 In our dataset, five patients were still alive, so we adjusted for the right censoring in the Cox proportional hazard model.
Survival was compared between negative and positive PD-L1 expression group to identify if there was a statistically significant difference between the two groups using the log-rank test. The Kaplan-Meier (KM) curves for PD-L1 positive and PD-L1 negative groups are plotted in Figure 1 , which shows the fraction of patients living for certain months in the two separate groups. This is an univariate analysis which did not adjust for confounding factors. For multivariate analysis, we fitted a Cox proportional hazard model to access if higher PD-L1 expression level was positively related to higher hazard rate, thus shorter survival time, after adjusting for confounding covariates in Table 1 . Specifically, the covariates included gender (male, female), ECOG level (1, 2 and 3), histology subtypes (epitheliod, sarcomatoid, biphasic), treatment (best supportive care, chemotherapy, combination chemotherapy/radiotherapy), and age (quadratic of age was also included to capture the nonlinear relationship). The statistical tests were two-sided and P-values smaller than 0.05 were considered as statistically significant. We reported the hazard ratios (HRs) and the associated 95% confidence intervals. Correlation between PD-L1 expression and histological subtype was calculated using Fisher's exact test.
RESULTS
Fifty-eight consecutive patients with pleural mesothelioma whose biopsy was available for analysis were included in the study. Median age was 73, majority was male (49, 84%). Forty-six (79%) had ECOG between 0 and 2, and 12 had ECOG of 3 (21%). Forty-two (72%) had epitheliod subtype, seven (12%) sarcomatoid subtype, and nine (16%) biphasic subtype. Thirty-one patients received best supportive care, 19 patients received chemotherapy and 8 patients received a combination of chemotherapy and radiotherapy. Sixteen (27.59%) patients were PD-L1 negative, 42 (72.43%) were found to be positive.
Pathologist concordance rate was 95%. All seven patients with sarcomatoid subtype (100%), 6 out of 9 biphasic subtype (67%), and 13 out of 42 epithelioid subtype patients (31%) had positive PD-L1 expression. There is no statistical significant correlation between PD-L1 positivity and subtypes using a Fisher's exact test (P-value = 0.2763).
In addition, we found 37 patients were TILs positive (64%). Twentyfour patients were PD-L1 positive/TILs positive (41.4%), 18 patients 
DISCUSSION
There is significant heterogeneity in survival of patients with MPM and being able to identify poor prognostic markers has important clinical implications. This can enable clinicians to determine patients who might need closer monitoring, or starting of systemic treatment earlier. Our study found that positive PD-L1 expression is associated with worse prognosis, with a difference in median survival time of 9.5 months between positive and negative groups. This is consistent with four previously published analyses. [9] [10] [11] [12] This study therefore contributes to a body of other published analyses to suggest that PD-L1 may be useful as a poor prognostic biomarker.
Sarcomatoid histological subtype correlates with poorer survival, and an association of PD-L1 expression with sarcomatoid histology has been reported by other studies. 12, 16 In our study, all patients with sarcomatoid subtype was found to have positive PD-L1 expression, consistent with findings in Mansfield et al., 12 however our study did not find a positive statistical correlation between different subtypes with PD-L1 expression and this may be due to our limited sample size. It is possible that PD-L1 expression may be a biomarker for the more aggressive sarcomatoid histological subtype, and subsequently confers worse prognosis. However, future confirmatory analyses should be performed to investigate whether PD-L1 expression is an independent prognostic biomarker, or a surrogate for sarcomatoid subtype.
Furthermore, a previous analysis has found that increased TILs is associated with PD-L1 positivity, and high TILs level is associated with poorer survival. 17 In our cohort, 24 patients out of 42 patients with positive PD-L1 expression were found to also be TILs positive (57%).
Our data have not included characterization of TILs level; therefore, 
F I G U R E 2 Examples of PD-L1 staining in tumor tissues
previous published analyses of PD-L1 expression in MPM has used a variation of cut-offs, 9-12 and a recent trial in NSCLC used a cutoff of 50%. 18 A high degree of inter-and intrasample heterogeneity makes classification into categorical (positive vs negative) groups difficult. A recent analysis has shown a spatial discordance of tumor cell PD-L1 expression in 14% between lung cancers and brain metastasis, and a nonstatistical significant temporal discordance of 11% in samples tested for expression between 6 months apart. 19 Utilizing a categorical cut-off has proven difficult and there is currently no consensus for this. However, the current rationale for choosing cut-off for determining on treatment options remains unclear and may vary depending on type of tumor tissue that is being assessed. The determination and interpretation of PD-L1 is further complicated by PD-L1 expressing macrophages and dendritic cells within the tumor and at the interface between tumor and stroma. 20 Our analysis does have a higher proportion (72%) of patients found to be positive, using a positivity cut-off of 1%, compared to four previously published analyses (21%, 25%, 42% and 40% PD-L1 positive in n = 119, 72, 329 and 106, with positivity cut off of 1%, 5%, 5% and 5% positivity cut-off respectively). [9] [10] [11] [12] This may be due to smaller sample size, and using lower positivity cut-off in our cohort. Our archival tissues were also predominantly video-assisted thoracoscopy speci- There are external quality assurance programme being developed to minimize the error and improve concordance among pathologists. 21 Our study has a number of limitations. Our small population size can limit statistical analysis. In addition, the retrospective nature of the study means variable record keeping accuracy, documentations quality may interfere with data integrity. Our data also included a higher proportion of patients not having chemotherapy (53% did not), and this differs to other previously published datasets. 4 This may be due to inclusion of patients from 2006, three years prior to pharmaceutical benefit schedule (PBS) approval to subsidize pemetrexed in the treatment of MPM. In the cohort of patients prior to this event, the majority of patients were aged older than 75, and this may explain why there was a higher rate of patients receiving best supportive care. This may also skew our survival time results.
The other important discussion surrounding PD-L1 as a biomarker in MPM is whether it can be used as a predictive marker to response to treatment, specifically to immunotherapy. In a retrospective analysis of 46 patients treated with PD-1 and PD-L1 inhibitors, PD-L1 testing was performed in 14 patients. 20 Nine patients were found to have positive PD-L1 (65%), with a cut-off of > 5%. Objective response rate was 40%
in PD-L1 positivity > 5%, and 50% in PD-L1 positivity > 50%, compared to only 22% in patients with negative expression. This analysis suggests that patients with positive PD-L1 might have a better response rate compared to PD-L1 negative patients. This will need to be further explored in larger prospective trials but again suggests another role of PD-L1 testing in patients with MPM.
CONCLUSION
In conclusion, our small analysis found a higher percentage of MPM 
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